Haematologica (Jun 2022)
Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
- Ayalew Tefferi,
- Naseema Gangat,
- Mithun Shah,
- Hassan Alkhateeb,
- Mrinal S. Patnaik,
- Aref Al-Kali,
- Michelle A. Elliott,
- William J. Hogan,
- Mark R. Litzow,
- Christopher C. Hook,
- Abhishek Mangaonkar,
- David Viswanatha,
- Dong Chen,
- Animesh Pardanani,
- Rhett P. Ketterling,
- Kebede H. Begna
Affiliations
- Ayalew Tefferi
- Department of Internal Medicine and Division of Hematology
- Naseema Gangat
- Department of Internal Medicine and Division of Hematology
- Mithun Shah
- Department of Internal Medicine and Division of Hematology
- Hassan Alkhateeb
- Department of Internal Medicine and Division of Hematology
- Mrinal S. Patnaik
- Department of Internal Medicine and Division of Hematology
- Aref Al-Kali
- Department of Internal Medicine and Division of Hematology
- Michelle A. Elliott
- Department of Internal Medicine and Division of Hematology
- William J. Hogan
- Department of Internal Medicine and Division of Hematology
- Mark R. Litzow
- Department of Internal Medicine and Division of Hematology
- Christopher C. Hook
- Department of Internal Medicine and Division of Hematology
- Abhishek Mangaonkar
- Department of Internal Medicine and Division of Hematology
- David Viswanatha
- Division of Hematopathology
- Dong Chen
- Division of Hematopathology
- Animesh Pardanani
- Department of Internal Medicine and Division of Hematology
- Rhett P. Ketterling
- Division of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN
- Kebede H. Begna
- Department of Internal Medicine and Division of Hematology
- DOI
- https://doi.org/10.3324/haematol.2022.281045
- Journal volume & issue
-
Vol. 107,
no. 10
Abstract
No abstracts available.
